Skip to main content
Erschienen in: Pediatric Nephrology 10/2003

01.10.2003 | Brief Report

Decrease of thrombomodulin contributes to the procoagulant state of endothelium in hemolytic uremic syndrome

verfasst von: Gabriela C. Fernández, Maroeska W. M. Te Loo, Thea J. A. van der Velden, Lambert P. W. van der Heuvel, Marina S. Palermo, Leo L. A. Monnens

Erschienen in: Pediatric Nephrology | Ausgabe 10/2003

Einloggen, um Zugang zu erhalten

Abstract

The typical form of hemolytic uremic syndrome (D+HUS) is a thrombotic microangiopathy that causes acute renal failure in children. The etiology of this disease is a toxin called Shiga-like toxin (Stx), present in certain strains of gram-negative bacteria. Vascular endothelial cell (EC) injury appears to be central in the pathogenesis of D+HUS. Thrombomodulin (TM) is a glycoprotein present in EC with anti-thrombogenic properties. The objective of this study was to investigate the effects of Stx on the surface expression of TM in EC using an in vitro culture of human glomerular microvascular endothelial cells. We also evaluated other inflammatory mediators [tumor necrosis factor-α (TNF-α) and lipopolysaccharide], which are known to increase Stx receptor expression and are potentially involved in the pathogenesis of D+HUS. Stx2 induced a significant decrease of TM expression in this cell type after pre-incubation with TNF-α. This decrease could not be attributed to the inhibition of protein synthesis only, as cycloheximide, another inhibitor of protein synthesis, did not affect TM surface expression. These results suggest that the Stx2-induced decrease of TM expression in glomerular EC might contribute to the local procoagulant state present in D+HUS.
Literatur
1.
Zurück zum Zitat Remuzzi G, Ruggenenti P (1995) The hemolytic uremic syndrome. Kidney Int 48:2–19PubMed Remuzzi G, Ruggenenti P (1995) The hemolytic uremic syndrome. Kidney Int 48:2–19PubMed
2.
Zurück zum Zitat Esmon CT (1995) Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J 9:946–955PubMed Esmon CT (1995) Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J 9:946–955PubMed
3.
Zurück zum Zitat He CJ, Kanfer A (1992) Quantification and modulation of thrombomodulin activity in isolated rat and human glomeruli. Kidney Int 41:1170–1174PubMed He CJ, Kanfer A (1992) Quantification and modulation of thrombomodulin activity in isolated rat and human glomeruli. Kidney Int 41:1170–1174PubMed
4.
Zurück zum Zitat Weiler-Guettler H, Christie PD, Beeler DL, Healy AM, Hancock WW, Rayburn H, Edelberg JM, Rosenberg RD (1998) A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest 101:1983–1991PubMed Weiler-Guettler H, Christie PD, Beeler DL, Healy AM, Hancock WW, Rayburn H, Edelberg JM, Rosenberg RD (1998) A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest 101:1983–1991PubMed
5.
Zurück zum Zitat Uchiba M, Okajima K, Murakami K, Johno M, Okabe H, Takatsuki K (1996) Recombinant thrombomodulin prevents endotoxin-induced lung injury in rats by inhibiting leukocyte activation. Am J Physiol 271:L470–L475PubMed Uchiba M, Okajima K, Murakami K, Johno M, Okabe H, Takatsuki K (1996) Recombinant thrombomodulin prevents endotoxin-induced lung injury in rats by inhibiting leukocyte activation. Am J Physiol 271:L470–L475PubMed
6.
Zurück zum Zitat Setten PA van, Hinsbergh VW van, Velden TJ van der, Kar NC van de, Vermeer M, Mahan JD, Assmann KJ, Heuvel LP van der, Monnens LA (1997) Effects of TNF alpha on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells. Kidney Int 51:1245–1256PubMed Setten PA van, Hinsbergh VW van, Velden TJ van der, Kar NC van de, Vermeer M, Mahan JD, Assmann KJ, Heuvel LP van der, Monnens LA (1997) Effects of TNF alpha on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells. Kidney Int 51:1245–1256PubMed
7.
Zurück zum Zitat Raife TJ, Demetroulis EM, Lentz SR (1996) Regulation of thrombomodulin expression by all-trans retinoic acid and tumor necrosis factor-alpha: differential responses in keratinocytes and endothelial cells. Blood 88:2043–2049PubMed Raife TJ, Demetroulis EM, Lentz SR (1996) Regulation of thrombomodulin expression by all-trans retinoic acid and tumor necrosis factor-alpha: differential responses in keratinocytes and endothelial cells. Blood 88:2043–2049PubMed
8.
Zurück zum Zitat Harel Y, Silva M, Giroir B, Weinberg A, Cleary TB, Beutler B (1993) A reporter transgene indicates renal-specific induction of tumor necrosis factor (TNF) by shiga-like toxin. Possible involvement of TNF in hemolytic uremic syndrome. J Clin Invest 92:2110–2116PubMed Harel Y, Silva M, Giroir B, Weinberg A, Cleary TB, Beutler B (1993) A reporter transgene indicates renal-specific induction of tumor necrosis factor (TNF) by shiga-like toxin. Possible involvement of TNF in hemolytic uremic syndrome. J Clin Invest 92:2110–2116PubMed
9.
Zurück zum Zitat Takano S, Kimura S, Ohdama S, Aoki N (1990) Plasma thrombomodulin in health and diseases. Blood 76:2024–2029PubMed Takano S, Kimura S, Ohdama S, Aoki N (1990) Plasma thrombomodulin in health and diseases. Blood 76:2024–2029PubMed
10.
Zurück zum Zitat Nevard CH, Blann AD, Jurd KM, Haycock GB, Hunt BJ (1999) Markers of endothelial cell activation and injury in childhood haemolytic uraemic syndrome. Pediatr Nephrol 13:487–492CrossRefPubMed Nevard CH, Blann AD, Jurd KM, Haycock GB, Hunt BJ (1999) Markers of endothelial cell activation and injury in childhood haemolytic uraemic syndrome. Pediatr Nephrol 13:487–492CrossRefPubMed
11.
Zurück zum Zitat Ozdemir S, Besbas N, Saatci U, Bakkaloglu A (1996) Plasma thrombomodulin concentrations in uraemic children. Nephrol Dial Transplant 11:2369–2370PubMed Ozdemir S, Besbas N, Saatci U, Bakkaloglu A (1996) Plasma thrombomodulin concentrations in uraemic children. Nephrol Dial Transplant 11:2369–2370PubMed
12.
Zurück zum Zitat Campbell WD, Lazoura E, Okada N, Okada H (2002) Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol 46:131–134PubMed Campbell WD, Lazoura E, Okada N, Okada H (2002) Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol 46:131–134PubMed
Metadaten
Titel
Decrease of thrombomodulin contributes to the procoagulant state of endothelium in hemolytic uremic syndrome
verfasst von
Gabriela C. Fernández
Maroeska W. M. Te Loo
Thea J. A. van der Velden
Lambert P. W. van der Heuvel
Marina S. Palermo
Leo L. A. Monnens
Publikationsdatum
01.10.2003
Verlag
Springer-Verlag
Erschienen in
Pediatric Nephrology / Ausgabe 10/2003
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-003-1236-8

Weitere Artikel der Ausgabe 10/2003

Pediatric Nephrology 10/2003 Zur Ausgabe

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.